【Keywords】 Human epidermal growth factor receptor 2 mutation; Breast cancer; Drug resistance; Target therapy 人表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)基因扩增阳性乳腺癌占所 有乳腺癌的20% ～ 30%,与肿瘤的高侵袭性,高复 发风险,进展快速及不良预后相关[1-2].以曲妥珠单 ...
但差异无统计学意义(P>0.05);采用一线化疗的Ⅲ~Ⅳ期肺腺癌患者中伴HER-2突变者中位无进展生存期比HER-2无突变者短(P<0.005),这表明HER-2基因突变很可能提示此类中晚期肺腺癌患者更易对化疗药物耐药;在HER-2基因突变对中晚期肺鳞癌一线化疗疗效影响的分析中并未发现HER-2基因突变与此类患者一线化疗的...
晚期HER-2阳性乳腺癌原发灶与转移灶异质性研究 研究目的:比较晚期人表皮生长因子受体2(human epidermal growth factor-2,HER-2)阳性乳腺癌患者原发灶与转移灶基因突变特征差异,肿瘤突变负荷(Tumor Mutation Burden,... 王慧,张咪,杨姣,... - Cctb中国肿瘤标志物学术大会暨中国整合肿瘤学大会暨肿瘤标志物青年科学家...
HER-2ALKROS1Lung adenocarcinomaHuman epidermal growth factor receptor(HER)-2is a driver gene in non-small cell lung cancer (NSCLC). The present study evaluated the mutation rate ofHER-2within the wild-typeepidermal growth factor receptor(EGFR) lung adenocarcinoma population in China. Formalin-...
摘要 目的研究乳腺癌中磷脂酰肌醇-3-激酶催化亚单位α(PIK3CA)基因突变与人表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)蛋白表达和基因扩增之间的关系,...展开更多 ObjectiveTo investigate the relationship between PIK3CA gene mutation and HER2 gene amplification and protein expression in ...
HER-2 gene amplification and protein overexpression has been associated with increased risk of advanced-stage breast cancer and poor prognosis. Recently, a single missense point mutation (Ile(655)Val) in the transmembrane domain of the HER-2 gene was associated with a 40% increase in breast canc...
Mutations inHERC2were also found in the two patients in whom the Notch2 mutation was identified, and the mutation originated from their mothers while the Notch2 mutation was inherited from their fathers. Their fathers were within the normal height range, but their mothers were lower in height ...
(HER-2)是一种原癌基因,其与多种肿瘤的发生、发展及预后关系密切,通过下游信号的转导参与肿瘤细胞增殖、凋亡、浸润及转移等的调控.HER-2的过表达与肿瘤患者不良总体预后相关.作为胃癌预后指标、治疗反应预测指标、治疗靶点,其可预测新辅助化疗的疗效,HER-2已成为国际肿瘤生物治疗的热点.该文就HER-2的生物学特征、...
To this purpose we evaluated the effect of T-DM1 in a panel of NSCLC cell lines with different HER-2 expression levels, in H1781 cell line carrying HER-2 mutation [20], and in gefitinib resistant HER-2 overexpressing PC9/HER2cl1 cell clone [14]. Moreover, we explored the correlation ...
Since human Her-2/neu gene has tyrosine kinas activity in the intracellular domain and its overexpression itself stimulates abnormal cell division, there are several attempts to eliminate possible oncogenecity of Her-2/neu by introducing a mutation into the cytoplasmic kinase domain to inhibit tyrosine...